Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of datopotamab deruxtecan with or without durvalumab versus chemotherapy plus pembrolizumab in PD-L1 positive metastatic or inoperable recurrent triple-negative breast cancer
2023-503675-24-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Datopotamab deruxtecan, Datopotamab deruxtecan + durvalumab and Investigator's choice chemotherapy + pembrolizumab (3 arms). Primary endpoint: Progression-free survival. Planned start Jan 2025; status: authorised.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-503675-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503675-24-00.